Sensex Today | Lupin receives EIR from USFDA for its Nagpur Injectable facility
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur, India, with a satisfactory Voluntary Action Indicated (VAI) classification.
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025.
Lupin was quoting at Rs 2,107.70, up Rs 18.05, or 0.86 percent.
It has touched an intraday high of Rs 2,127.40 and an intraday low of Rs 2,090.75.
It was trading with volumes of 13,139 shares, compared to its five day average of 24,629 shares, a decrease of -46.65 percent.
In the previous trading session, the share closed down 0.02 percent or Rs 0.50 at Rs 2,089.65.
The share touched a 52-week high of Rs 2,403.45 and a 52-week low of Rs 1,774.00 on 02 January, 2025 and 07 April, 2025, respectively.
Currently, the stock is trading 12.31 percent below its 52-week high and 18.81 percent above its 52-week low.
Market capitalisation stands at Rs 96,279.48 crore.